Suven Pharmaceuticals announced that CRISIL has assigned the rating `CRISIL A+/ Watch Positive (placed on rating watch with positive implications) / CRISIL A1+ (reaffirmed) for bank facilities of the company. Powered by Capital Market - Live News

The Board of Suven Pharmaceuticals at its meeting held on 29 February 2024 has approved a scheme of amalgamation of Cohance Lifesciences (transferor company) into and with the Company.Powered by Capital Market - Live News

Suven Pharmaceuticals announced that its Active Pharmaceutical Ingredients (API) and Formulations facilities (Unit-3 and Unit-5, respectively) in Pashamylaram, Hyderabad, India, have completed the Pre Approval Inspections (PAI) and Good Manufacturing Practices (GMP) inspections by the US Food & Drug Administration (US FDA) today. The inspection was conducted from 12 February 2024, to 23 February 2024, and no Form 483 has been issued as a result of the inspectionPowered by Capital Market - Live News

Net profit of Suven Pharmaceuticals declined 56.60% to Rs 46.75 crore in the quarter ended December 2023 as against Rs 107.72 crore during the previous quarter ended December 2022. Sales declined 37.86% to Rs 219.82 crore in the quarter ended December 2023 as against Rs 353.77 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales219.82353.77 -38 OPM %29.6441.47 - PBDT78.22158.32 -51 PBT65.47146.08 -55 NP46.75107.72 -57 Powered by Capital Market - Live News

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 February 2024. The meeting would commence at 4.00 pm.Powered by Capital Market - Live News